BenchCost

BenchCost is a self-reported browser-based planning tool for research labs, designed to estimate experimental costs before lab entry. The author states it supports Western blot experiments with an 11-step workflow and interactive cost calculation. It uses a deterministic engine and integrates with OpenAI Codex (GPT-5.6) for development support.

The project appears to be a single-person effort built as a Next.js/React application using TypeScript and Tailwind CSS. The author claims the tool enables live recalculation, linked-change previews, antibody compatibility guidance, and export capabilities.

Key commercial due-diligence question: Does BenchCost have any evidence of market traction or customer validation beyond the author's own development?

The description is self-reported and unverified. No revenue, customers, or adoption data are provided. The tool is described as a prototype for Western blot experiments only. There is no indication of any commercial activity or product-market fit.

• The description states BenchCost is a browser-based planning tool
• It is built using Next.js, React, TypeScript, and Tailwind CSS
• It uses OpenAI Codex with GPT-5.6 for development support
• The current version supports Western blot experiments only
• It operates as an interactive workspace that connects experimental inputs to cost calculations
• It includes a deterministic cost engine that recalculates costs when inputs change

Inference: Based on the description, BenchCost appears to be a web application that allows researchers to plan experiments by entering parameters and seeing how changes affect costs. The tool is described as having an 11-step workflow for Western blot protocols.

• The author states BenchCost was built to solve the problem of fragmented planning work across protocols, vendor catalogs, lab inventory, spreadsheets, and assumptions
• It positions itself as a tool that turns scattered planning into "one explainable estimate before anyone enters the lab"
• The product claims to support live recalculation, editable workflows, linked previews, antibody compatibility guidance, and export capabilities
• The author notes they learned that "experimental cost is a property of the entire workflow, not a single price list"

Inference: BenchCost evolved from a problem-solving approach focused on lab planning inefficiencies. The positioning appears to be about improving research lab efficiency through better cost estimation tools.

• The description states it targets "research teams" who understand biology but struggle with planning questions
• It is specifically designed for lab-based researchers working with Western blot experiments
• The tool is described as helping users avoid scattered planning work across multiple sources
• The author mentions "institution-specific inventory" as a future feature, suggesting institutional use

Inference: The primary customer appears to be individual researchers or small research teams in life sciences labs. The ICP seems to be those who perform Western blot experiments and need cost planning tools.

• Not evidenced
• The description does not mention any pricing model, monetization strategy, or business model details
• No information about revenue streams, customer acquisition costs, or unit economics is provided

Inference: There is no evidence of a defined business model or pricing structure in the self-reported description.

• Built as a browser-based application using Next.js, React, TypeScript, and Tailwind CSS
• Uses OpenAI Codex with GPT-5.6 for implementation support, UX iteration, English localization, and QA
• Features include: live recalculation, editable 11-step workflow, linked-change previews, antibody compatibility guidance, line-item cost assumptions, unresolved-input tracking, local draft saving, JSON/CSV export
• The tool is described as having a deterministic cost engine that connects inputs to workflow steps

Inference: The technical approach appears to be modern web development with AI-assisted development. The delivery signals suggest a functional prototype with interactive features.

• The project was submitted to the OpenAI 2026 hackathon
• It is described as a prototype for Western blot experiments only
• The team size is listed as one person (Yu Nabeshima)
• No revenue, customer adoption, or usage metrics are mentioned
• The author states they will collect "more than one million data points" to support expanded functionality

Inference: There is no evidence of product-market fit, customer traction, or commercial viability. The tool appears to be in early development stage.

• Not evidenced
• No mention of existing competitors or market landscape
• No information about how BenchCost differentiates from other lab planning tools or cost estimation systems
• No reference to similar products or market positioning against existing solutions

Inference: The competitive context is unknown based on the provided description.

• Single-person development team (team size: 1)
• Prototype-only functionality (Western blot only)
• No revenue, customers, or traction data
• Self-reported and unverified claims about functionality
• No evidence of market validation or product-market fit
• The tool appears to be in early development stage with no commercial activity

Inference: The main risks include lack of team capacity, limited functionality scope, absence of commercial traction, and unvalidated assumptions about customer needs.

1. What specific research labs or institutions have shown interest in this tool?
2. How do you plan to expand beyond Western blot protocols?
3. What is your strategy for collecting the "more than one million data points" mentioned?
4. Have you validated the cost assumptions with actual lab data?
5. What are your plans for monetization and customer acquisition?
6. How do you intend to scale from a single-person development team?
7. What specific problems have researchers identified that BenchCost solves?